

1 Collapsed Haplotype Pattern Method for Linkage Analysis of Next-Generation Sequence Data

2 Gao T. Wang^{1, §}, Di Zhang^{1, §}, Biao Li¹, Hang Dai¹, Suzanne M. Leal^{1*}

3
4 ¹Center for Statistical Genetics, Department of Molecular and Human Genetics, Baylor College of
5 Medicine, Houston, TX 77030, USA

6 [§]These authors contribute equally to this work.

7 *Correspondence:

8 Suzanne M. Leal

9 Department of Molecular and Human Genetics

10 Baylor College of Medicine

11 One Baylor Plaza, 700D

12 Houston, TX 77030

13 713-798-4011

14 sleal@bcm.edu

15 Running title: Linkage Method for Next-Generation Sequence Data

16 **Abstract**

17 Recent advances in next generation sequencing (NGS) make it possible to directly sequence
18 genomes and exomes of individuals with Mendelian diseases and screen sequence data for causal
19 variants. With the reduction in cost of NGS, DNA samples from entire families can be sequenced
20 and linkage analysis can be performed directly using NGS data. Inspired by “burden” tests which
21 are used for complex trait rare variant association studies, we developed the collapsed haplotype
22 pattern (CHP) method for linkage analysis. Using data from several deafness genes we
23 demonstrate that the CHP method is substantially more powerful than analyzing individual
24 variants. Unlike applying NGS data filtering approaches, the CHP method provides statistical
25 evidence of a gene’s involvement in disease etiology and is also less likely to exclude causal
26 variants in presence of phenocopies and/or reduced penetrance. The CHP method was
27 implemented in the SEQLinkage software package which can perform linkage analysis on NGS
28 data or can generate data compatible with many linkage analysis programs, reviving them for use
29 in NGS era.

30 **Keywords**

31 Parametric linkage analysis, LOD scores, Mendelian diseases and traits, Next-generation
32 sequence data, Statistical method.

33 Introduction

34 The advent and advance of NGS in recent years has led to the identification of a large number of
35 Mendelian disease genes. The typical approach to identifying Mendelian disease causal variants
36 using either whole genome sequence (WGS) or exome sequence (WES) data is to filter variants in
37 an affected individual or shared by affected family members, excluding those which are found at
38 higher frequencies, e.g. $>0.5\%$ in variant databases. Sometimes unaffected family member(s) are
39 also used in the filtering process. While filtering is straightforward and has been successful¹, such
40 efforts rely on limited family information, e.g. mode of inheritance, sharing between a subset of
41 family members and information from external resources on variant functional characterizations
42 and frequencies. On the other hand, linkage analysis, which incorporates information on mode of
43 inheritance, penetrance, allele frequencies and genetic map information, remains a powerful tool
44 to localize Mendelian disease loci. As a result, combined SNP array based linkage analysis and
45 sequence based filtering method is becoming popular². There is also a great interest to directly
46 perform linkage analysis on rare variants obtained from NGS data. Although it has been shown
47 that analyzing rare single nucleotide variants (SNVs), usually designated as having a minor allele
48 frequency (MAF) $<0.5\%$ or 1% , from NGS data provides acceptable linkage results, due to low
49 heterozygosity of SNVs and allelic heterogeneity this approach can be less powerful than analysis
50 of SNPs from genotyping arrays³.

51 Here we describe the collapsed haplotype pattern (CHP) method which is motivated by rare variant
52 association methods which analyze multiple rare variants within a region, which is often a gene.
53 The CHP method was designed to analyze rare variants by constructing markers that have a higher

heterozygosity and are more informative for linkage analysis than individual rare SNVs. Unlike when SNPs are analyzed, the CHP method does not require linkage disequilibrium (LD) pruning to avoid spurious associations⁴. The CHP method is particularly powerful in the presence of intra- (e.g. compound heterozygotes) and inter-family allelic heterogeneity, a phenomenon commonly observed for Mendelian diseases. When causal variants are missing from samples, the CHP method can still detect linkage due to transmission information retained by other variants. We have developed the SEQLinkage software package implementing the CHP method. Since SEQLinkage can test for linkage heterogeneity and calculate Heterogeneity LOD (HLOD) scores the CHP method remains powerful when there is locus heterogeneity, i.e. the underlying genetic etiology is not due to the same gene/region in all families.

Materials and Methods

For the CHP method instead of analyzing each variant separately, multiple variants which form haplotypes within a genetic region, e.g. gene, are analyzed. This is done by constructing a marker which reflects the transmission pattern of the entire region and is numerically compatible with currently available linkage analysis methods and software. These markers incorporate allelic heterogeneity between and within families in a region and often have higher heterozygosity than SNVs, making them more informative and powerful to detect linkage.

To generate regional markers, haplotypes for the region must be obtained for all samples with sequence data. NGS data from family members are first checked for Mendelian errors and variants with Mendelian inconsistencies are removed. An improved version of the Lander-Green algorithm

for genetic phasing is applied to reconstruct haplotypes in the pedigrees⁵. For each pedigree, we first cluster variants on regional haplotypes by “bins”, e.g. LD blocks, and collapse variants in a bin into an indicator variable with values 0 or 1 for having no minor allele or at least one minor allele within the bin, which is similar to collapsing methods for rare variant association analysis⁶. We then assign each collapsed haplotype a single numeric value so that different patterns of collapsed haplotypes in each pedigree are uniquely represented (Figure 1). The choice of coding for patterns are arbitrary, although we use continuous positive integers and assign a smaller value for collapsed haplotypes having more 0’s than 1’s. The sample haplotypes thus represented can be directly used for parametric linkage analysis with many existing linkage software packages.

For WES data, genes can be used as regional markers. Within each region, commonly used bin size options for variants collapsing are 1) LD based collapsing, which uses estimated LD blocks as bins, 2) complete collapsing, whose bin size equals gene/region length and 3) no collapsing, whose bin size equals one. For regions where recombination events occur within a family, the sub-unit that shows the strongest evidence of linkage among all sub-units created by recombination breakpoints is used as the regional LOD score for the family, so that results from multiple families can still be combined.

In order to reconstruct genotypes for family members missing sequence data, linkage analysis requires marker allele frequencies. Frequencies of regional markers generated by CHP method can be derived from minor allele frequencies (MAF) of variants and pair-wise LD between variants. For rare variants with MAF derived from large samples (see Discussion), the minor allele counts can be approximated by a multivariate Poisson distribution with joint probability mass function

95 $P(\mathbf{X}) = f_{(\lambda, \theta)}(\mathbf{X})$ where $\lambda_{M \times 1}$ is expected allele counts for M variants and $\theta_{M \times M}$ is the variance-
 96 covariance matrix⁷. The covariance between variants X_i and X_j can be computed by
 97 $\text{cov}(x_i, x_j) = r_{ij} N \sqrt{p_i p_j (1 - p_i)(1 - p_j)}$ where r_{ij}^2 is the LD coefficient, p is population MAF
 98 and N is the sample size based on which population MAF are estimated. Therefore for a given
 99 haplotype pattern $\mathbf{x}_H = [x_1, x_2, \dots, x_M]$, $x_k \in \{0, 1\}$ the corresponding frequency $f_{(\lambda, \theta)}(\mathbf{X} = \mathbf{x}_H)$ can
 100 be computed from the probability mass function. When collapsing is applied, MAF for the
 101 collapsed unit is given as $1 - f_{(\lambda, \theta)}(\mathbf{X} = [0, 0, 0, \dots])$ by definition. Collapsed haplotype pattern
 102 frequencies thus computed are then used as the allele frequencies for the corresponding regional
 103 genotype markers.

104 To facilitate linkage analysis using sequence data in VCF format, we developed the SEQLinkage
 105 software that uses the Elston-Stewart algorithm as incorporated in FASTLINK⁸. It provides results
 106 in text format and high quality graphical reports for both LOD and HLOD scores. Additionally
 107 SEQLinkage supports output of regional genotype data into formats compatible with linkage
 108 software such as LINKAGE⁹ and Merlin¹⁰, with which two-point and multipoint parametric
 109 linkage analysis can be performed. Additionally MEGA2¹¹ format is supported, which can be used
 110 to transform data to the required input for a number of linkage programs.

111 To evaluate performance of our method we performed empirical type I error and power
 112 calculations for two-point linkage analysis using data on four non-syndromic hearing impairment
 113 (NSHI) genes: two autosomal recessive genes *GJB2* and *SLC26A4*, and two autosomal dominant
 114 genes *MYO7A* and *MYH9*. Two-generation pedigrees were simulated, with 3 to 8 offspring in the

115 last generation with the proportions determined by the distribution of number of children per
116 family in the United States in 2012, rescaled so that they sum to 100% (3 children: 69.34%, 4
117 children: 20.52%, 5 children: 6.84%, 6 children: 2.28%, 7 children 0.76%, 8 children 0.26%).
118 Genotypes are simulated for the four genes based on the variant sites and the corresponding minor
119 allele frequencies in European Americans recorded in the Exome Variant Server.

120 For type I error evaluations we use the same gene sequences and demographic data, yet simulate
121 disease pedigrees under the null, i.e., affection status not due to any of the rare variants in the gene
122 of interest. We consider different genetic architectures under the null including situations when 1)
123 variants in the gene region are in linkage equilibrium, 2) there is complete LD between variants
124 and 3) there exist within a gene recombination events in the sequence data of generated families.
125 Recombination events between variants are simulated based on rates obtained from Hapmap
126 Recombination Rates and Hotspots database (see Web Resources). Additionally we simulate
127 scenarios when parental genotypes are missing to evaluate type I error when CHP marker
128 frequencies have to be calculated using population MAF and LD estimated from data. Type I errors
129 are computed for cumulative HLOD scores on gene *SLC26A4* across 20 families using 2,000,000
130 replicates.

131 For power evaluations we annotate variants in these four NSHI genes using Deafness Variation
132 Database (DVD) and NCBI ClinVar, labelling variants as “causal” if they are so deemed by both
133 databases. Disease status for individuals are determined by genotypes on those causal sites under
134 dominant mode of inheritance for *MYO7A* and *MYH9*, and recessive (compound heterozygotes
135 and homozygotes) for *GJB2* and *SLC26A4*, assuming complete penetrance. Additionally for each

mode of inheritance we allow for allelic heterogeneity among families, i.e., the causal variant site in a gene may not be the same for different families. We “ascertain” simulated families having two or more affected offspring for linkage analysis. To introduce locus heterogeneity we sample families having causal variants in one gene but not the other, so that each simulated gene contributes to etiology of only a proportion of families in the entire dataset. We simulate 500 replicates under each different setting of sample size, mode of inheritance, presence of allelic heterogeneity and locus heterogeneity. For each replicate we compute LOD and HLOD scores using the CHP method. For comparison purposes we also analyze SNV markers and perform multipoint linkage analysis, with multipoint linkage analysis being performed using GeneHunter¹². Power is estimated by $P = \frac{N_{success}}{N}$ where the denominator is the total number of replicates and the numerator is the number of tests that successfully detected the linkage signal, i.e. LOD score greater than 3.3 or HLOD score greater than 3.6 which provides a genome wide significance level of $p < 0.05$ ¹³.

Results

Empirical type I error for the CHP linkage statistic is $\hat{\alpha} = 2.8 \times 10^{-5}$ (95% CI: $2.11 \times 10^{-5} \leq \alpha \leq 3.63 \times 10^{-5}$), demonstrating that type I error is well controlled and even conservative at a required α level of 4.7×10^{-5} for an HLOD of 3.6. Quantile-Quantile (QQ) plots are generated to evaluate the null distribution of test statistic in the presence of within-gene recombination, strong inter-marker LD and missing genotype data; type I error is well controlled and no sign of inflation is observed (Figure S1). Empirical power calculations for several known

non-syndromic hearing loss genes using the CHP method as well as for individual SNV are summarized by contour plots (Figures 2). Power analysis based on LOD and HLOD suggests that CHP is substantially more powerful for all models in the presence of intra- (Figure 2C) and inter-family allelic heterogeneity (Figures 2A–2C). For example to detect linkage with the *SLC26A4* gene using an autosomal recessive model with allelic heterogeneity, i.e. compound heterozygotes, and also with locus heterogeneity of 50%, 12 families are required for the CHP method to achieve a power of 90%, while analyzing individual SNVs requires >50 families to achieve the same power at a genome wide significance level of $\alpha=0.05$. Additionally, although multipoint linkage analysis is more powerful than analyzing SNVs, the CHP method is considerably more powerful than multipoint linkage analysis (Table S1).

For sequence data, variants are sometimes missing due to the inability to call variants or during quality control, variant calls are removed because of poor data quality. Therefore we also estimated sample size requirements for the CHP method when causal variants are missing from sequence data in a large proportion of families, i.e. 75%. The CHP method can tolerate missing data and is also always more powerful than the SNV method when there is missing data (Table 1).

Discussion

For linkage analysis, correct specification of marker allele frequency is crucial for controlling type I error and reducing type II error¹⁴. The number of founders with available genotypes in data for linkage analysis might often be too small to obtain a sufficiently accurate allele frequency estimate, thus we recommend the input VCF file be annotated with an external source of MAF information,

e.g. 1000 Genomes or Exome Variant Server. For some populations MAF information may not be available and frequencies estimated from founders have to be used.

In the context of Mendelian disease mapping it is reasonable to assume that common variants (variants having population $MAF > 1\%$) are not directly causal. Analyzing common variants will neither contribute to nor reduce power when analyzed with rare variants. Common variants can be in strong LD with variants in neighboring regions which may contain causal variants; thus when the CHP method is used to construct the regional marker also using common variants, linkage can be detected even though the region does not harbor any causal variants. Although common variants should not be used when constructing regional markers, we suggest analyzing common variants separately because they can potentially capture additional information when rare causal variants are missing from sequence data.

Analysis of rare variants using “burden” methods are usually limited to those variants which are most likely to be causal, e.g. missense, nonsense and splice site variants, because inclusion of non-causal variants can attenuate the association signal and reduce power. For the CHP methods inclusion of non-causal rare variants will not attenuate the linkage signal and therefore analysis does not need to be restricted to variants which are most likely functional and causal. Inclusion of non-causal rare variants to construct the region marker can provide additional linkage information if data for causal variants are missing. If the goal is to detect a linkage signal from variants which are potentially causal then linkage analysis using the CHP method can be limited to those variant sites which are most likely functional.

196 In addition to the CHP method being more powerful than performing multipoint linkage analysis,
197 it also controls type I error when there is missing parental genotype data and inter-marker LD,
198 which is not the case for multipoint linkage analysis. Caution should be used when performing
199 multipoint linkage analysis on sequence data, since when parental genotypes are missing for some
200 samples (common for NGS based family data) variants in LD can lead to serve inflated type I error
201 when markers are assumed to be in linkage equilibrium^{15,16}. The majority of multipoint linkage
202 analysis programs e.g. GeneHunter, SuperLink¹⁷, Vitesse¹⁸, do not take into consideration LD
203 between marker loci. Even for linkage programs that can model inter-marker LD, e.g.,
204 LINKAGE/FASTLINK and Merlin, the haplotype frequency estimates involving rare variants can
205 be inaccurate for studies with limited number of founders, leading to inflated type I error.

206 The SEQLinkage package, freely available at URL <http://bioinformatics.org/seqlink>, can
207 efficiently extract genotypes from VCF files and uses the CHP method described here to perform
208 linkage analysis as well as data format conversion on sequence data so that other programs can
209 also be used to perform linkage analysis if desired. It provides a novel and effective approach that
210 brings back well established linkage analysis techniques for use with the growing wealth of
211 genomic data of human pedigrees. Unlike filtering approaches which are commonly used to
212 analyze sequence data, SEQLinkage provides statistical evidence of the involvement of variants
213 in the etiology of Mendelian diseases. Additionally because it incorporates mode of inheritance
214 information and penetrance models it is less likely than filtering approaches to exclude causal
215 variants in the presence of phenocopies and/or reduced penetrance. For Mendelian traits for which
216 the penetrance model is not well established but the mode of inheritance is known, an affected-
217 only analysis can be performed where all unaffected individuals are made unknown to avoid

218 decreased power due the use of an incorrect penetrance model. We recommend the use of
219 SEQLinkage in parallel to filtering methods on the same sequence data to take full advantage of
220 the power of NGS in families.

221 **Acknowledgements**

222 The authors would like to thank Regie Lyn Santos-Cortez, Daniel Weeks, Alejandro Schaffer,
223 Jeffrey O’Connell and Jurg Ott for helpful discussions and support. This work is funded by
224 National Institute of Health (DC003594, DC011651 and HG006493).

225 *Conflict of Interest: none declared.*

226 **References**

- 227 1 Ng SB, Buckingham KJ, Lee C *et al.* Exome sequencing identifies the cause of a mendelian
228 disorder. *Nat Genet* 2010; **42**: 30–35.
- 229 2 Santos-Cortez RLP, Lee K, Azeem Z *et al.* Mutations in KARS, Encoding Lysyl-tRNA
230 Synthetase, Cause Autosomal-Recessive Nonsyndromic Hearing Impairment DFNB89. *Am J*
231 *Hum Genet* 2013; **93**: 132–140.
- 232 3 Smith KR, Bromhead CJ, Hildebrand MS *et al.* Reducing the exome search space for
233 Mendelian diseases using genetic linkage analysis of exome genotypes. *Genome Biol* 2011;
234 **12**: R85.
- 235 4 Huang Q, Shete S, Amos CI. Ignoring linkage disequilibrium among tightly linked markers
236 induces false-positive evidence of linkage for affected sib pair analysis. *Am J Hum Genet*
237 2004; **75**: 1106–1112.

- 238 5 Abecasis GR, Wigginton JE. Handling Marker-Marker Linkage Disequilibrium: Pedigree
239 Analysis with Clustered Markers. *Am J Hum Genet* 2005; **77**: 754–767.
- 240 6 Li B, Leal SM. Methods for detecting associations with rare variants for common diseases:
241 application to analysis of sequence data. *Am J Hum Genet* 2008; **83**: 311–321.
- 242 7 Karlis D. An EM algorithm for multivariate Poisson distribution and related models. *J Appl*
243 *Stat* 2003; **30**: 63–77.
- 244 8 Cottingham RW Jr, Idury RM, Schäffer AA. Faster sequential genetic linkage computations.
245 *Am J Hum Genet* 1993; **53**: 252–263.
- 246 9 Lathrop GM, Lalouel JM, Julier C, Ott J. Strategies for multilocus linkage analysis in
247 humans. *Proc Natl Acad Sci* 1984; **81**: 3443–3446.
- 248 10 Abecasis GR, Cherny SS, Cookson WO, Cardon LR. Merlin--rapid analysis of dense genetic
249 maps using sparse gene flow trees. *Nat Genet* 2002; **30**: 97–101.
- 250 11 Mukhopadhyay N, Almasy L, Schroeder M, Mulvihill WP, Weeks DE. Mega2: data-
251 handling for facilitating genetic linkage and association analyses. *Bioinformatics* 2005; **21**:
252 2556–2557.
- 253 12 Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage
254 analysis: a unified multipoint approach. *Am J Hum Genet* 1996; **58**: 1347–1363.
- 255 13 Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and
256 reporting linkage results. *Nat Genet* 1995; **11**: 241–247.

- 14 Freimer NB, Sandkuijl LA, Blower SM. Incorrect specification of marker allele frequencies: effects on linkage analysis. *Am J Hum Genet* 1993; **52**: 1102–1110.
- 15 Huang Q, Shete S, Swartz M, Amos CI. Examining the effect of linkage disequilibrium on multipoint linkage analysis. *BMC Genet* 2005; **6**: S83.
- 16 Li B, Leal SM. Ignoring Intermarker Linkage Disequilibrium Induces False-Positive Evidence of Linkage for Consanguineous Pedigrees when Genotype Data Is Missing for Any Pedigree Member. *Hum Hered* 2008; **65**: 199–208.
- 17 Fishelson M, Geiger D. Exact genetic linkage computations for general pedigrees. *Bioinforma Oxf Engl* 2002; **18 Suppl 1**: S189–198.
- 18 O’Connell JR, Weeks DE. The VITESSE algorithm for rapid exact multilocus linkage analysis via genotype set-recoding and fuzzy inheritance. *Nat Genet* 1995; **11**: 402–408.

Web Resources

- America's Families and Living Arrangements, <https://www.census.gov/prod/2013pubs/p20-570.pdf>
- Exome Variant Server (EVS), <http://evs.gs.washington.edu/EVS>
- Deafness Variation Database (DVD), <http://deafnessvariationdatabase.com>
- NCBI ClinVar, <https://www.ncbi.nlm.nih.gov/clinvar>
- Hapmap Recombination Rates and Hotspots database,

276 <http://hapmap.ncbi.nlm.nih.gov/downloads/recombination/latest/rates/>

Figure legends

Figure 1. Coding of regional markers using the Collapsed Haplotype Pattern (CHP) method.

Three two-generational autosomal recessive pedigrees display the coding for a regional marker using information from six variant sites. Panel A shows two families segregating the same autosomal recessive disease which is due to different causal variants. Treating the entire region as a bin to collapse the variants effectively captures transmission of disease variants and allows for linkage information for a region to be summed across families. For regions with more diverse rare variant architecture as displayed in Panel B, where for this example disease etiology is caused compound heterozygotes variants, coding which represents both rare variant haplotypes is used to ensure that all meioses are informative. It should be noted that if coding as is shown in Panel A is used in this situation there will be a loss of information because all heterozygous offspring will be uninformative for linkage information, e.g. the meioses to offspring II:1 and II:4.

Figure 2. Power comparisons for LOD and HLOD statistics in two-point linkage analyses.

This figure shows the power for collapsed haplotype pattern markers (CHP) vs. single nucleotide variant (SNV) analysis under various modes of inheritance in the presence of intra- and inter-family allelic heterogeneity. X-axis is number of families, Y-axis is proportion of locus heterogeneity, i.e. the proportion of families with non-syndromic hearing impairment (NSHI) caused by detrimental variants in the gene under investigation, i.e. either *MYO7A* or *MYH9* for dominant model, or *GJB2* or *SLC26A4* for recessive model. Contour curves on the graphs are power estimates, dark orange lines for the CHP method and light blue lines for SNV analysis. Panel A displays the power for the LOD and HLOD statistics under an autosomal dominant model; panel B displays the power for the LOD and HLOD statistics under an autosomal recessive model; panel C displays the power for the LOD and HLOD statistics under an autosomal recessive model

300 in the presence of intra-family allelic heterogeneity, i.e. affected individuals are compound
301 heterozygous. CHP method is more powerful for both LOD and HLOD at a genome-wide
302 significance level of $\alpha=0.05$, but the absolute power of HLOD is not significantly larger than LOD.
303 This is due to the very low MAFs for the genes under study and therefore for most families all
304 variants in the non-causal gene are monomorphic and therefore are uninformative.

305

307 **Table 1: Sample size estimates for the simulated nonsyndromic hearing impairment study.**

308

Required Power	Gene	MOI	CHP ¹	SNV ²	CHP-M75% ³	SNV-M75%
0.8	<i>SLC26A4</i>	recessive	11	40	39	160
0.9	<i>SLC26A4</i>	recessive	13	45	46	180
0.8	<i>SLC26A4</i>	compound recessive	11	50	39	200
0.9	<i>SLC26A4</i>	compound recessive	13	55	46	220
0.8	<i>GJB2</i>	recessive	12	23	44	92
0.9	<i>GJB2</i>	recessive	14	28	52	112
0.8	<i>GJB2</i>	compound recessive	12	25	44	100
0.9	<i>GJB2</i>	compound recessive	14	34	52	136
0.8	<i>MYO7A</i>	dominant	12	16	31	64
0.9	<i>MYO7A</i>	dominant	14	20	36	80
0.8	<i>MYH9</i>	dominant	11	13	32	52
0.9	<i>MYH9</i>	dominant	14	18	41	72

Note: 50% locus heterogeneity is assumed for all scenarios.

¹Number of families required for CHP method.

²Number of families required for single variant method.

³“M-75%”: number of families required when causal variants in 75% participating families are missing.